Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)
Your plan will be fully personalized, from the dosage to any complementary therapies, so that you have the best shot at reaching your goals and sustaining them
This policy reflects advice from professional bodies, such as the American College of Occupational and Environmental Medicine (ACOEM), which notes that the present availability of coverage for obesity care is piecemeal and calls for guidance on how to operationalize evidence-based behavioral, nutritional, pharmacological, and surgical obesity treatment modalities as health benefits. The ACOEM further notes that obesity represents an ongoing cost to employers and society at large in the form of current and future health care expenses, absenteeism, presenteeism, and workers compensation costs related to injuries and illnesses. OPMs 2025 Call Letter, issued January 15, 2025, identified this context of rising utilization and cost amidst inconsistent application of comprehensive, evidence-based care
PMID: 35983423
Front Endocrinol (Lausanne) 8:197
Both in vitro and in vivo hepatoprotective activities of C
